Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
Iraj Hosseini, Saroja Ramanujan(Unknown), Liping Sun(Chinese Academy of Agricultural Sciences), Chi‐Chung Li, Yu‐Waye Chu, Kapil Gadkar(Sea Turtle Conservancy), Eric Stefanich
Cited by 119
Related Papers
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
|The Lancet Oncology|2022|429
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
|Immunity|2005|317
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267